Baricinix 2MG & 4MG (Baricitinib)
Product Name : Baricinix(Baricitinib)
Generic Name : Baricitinib
Formulation : Tablet
Available Pack Size : 30’s Pot
Available Strengths : 2mg & 4mg
Registrations : 08.07.2021
Product Information
Baricinix (Baricitinib) 2mg and 4mg is a selective and reversible JAK1 and JAK2 inhibitor used to treat moderate to severe active Rheumatoid Arthritis (RA) in adult patients who have not responded adequately to one or more disease-modifying anti-rheumatic drugs (DMARDs). It works by partially inhibiting Janus kinase (JAK1 and JAK2) enzymatic activity, thereby reducing the phosphorylation and activation of signal transducers (STATs) that drive inflammation and abnormal immune response. Manufactured by Beacon Pharmaceuticals Ltd., Bangladesh and globally supplied by Mediaid Pharmacy with worldwide shipping.
Basic Product Information of Baricinix (Baricitinib) 2mg and 4mg
| Brand Name | Baricinix (Baricitinib) |
| Generic Name | Baricitinib INN |
| Drug Class | Selective and Reversible JAK1 and JAK2 Inhibitor (Janus Kinase Inhibitor) |
| Available Strengths | 2mg and 4mg |
| Formulation | Film-Coated Tablet |
| Pack Size | 30 Tablets per Pot |
| Primary Indication | Moderate to Severe Active Rheumatoid Arthritis (RA), Atopic Dermatitis and Alopecia Areata |
| Regulatory Approvals | USFDA Approved (RA, Atopic Dermatitis, Alopecia Areata). EMA Approved (RA and Atopic Dermatitis). FDA Emergency Use Authorization (EUA) for severe COVID-19. |
| Originator Brand | Olumiant by Eli Lilly and Incyte |
| Manufacturer | Beacon Pharmaceuticals Ltd., Mymensingh, Bangladesh |
| Global Supplier | Mediaid Pharmacy, Worldwide Shipping Available |
| Registration Date | 08/07/2021 |
| Storage Conditions | Store below 30 degrees Celsius. Keep in a dry place away from light and moisture. Keep out of the reach of children. |
How Baricinix (Baricitinib) Works
Baricinix contains Baricitinib, a selective and reversible inhibitor of Janus kinase enzymes JAK1 and JAK2. Janus kinases are intracellular enzymes that transmit signals from the surface of immune cells in response to cytokines and growth factors involved in haematopoiesis, inflammation, and immune function. In conditions such as rheumatoid arthritis, these signalling pathways become overactive, leading to chronic inflammation and progressive joint damage.
Baricitinib works by partially inhibiting JAK1 and JAK2 enzymatic activity, thereby reducing the phosphorylation and activation of signal transducers and activators of transcription (STATs). By modulating these pathways, Baricinix interrupts the cascade of inflammatory signals that cause joint pain, swelling, stiffness, and tissue destruction in rheumatoid arthritis and other autoimmune conditions.
Unlike biologics that are administered by injection, Baricinix is a convenient once-daily oral tablet, offering patients an effective and easy-to-use treatment option. Its selective mechanism of action means it targets the specific pathways driving disease while minimising unnecessary disruption to other immune functions.
Indications for Baricinix (Baricitinib)
Baricinix (Baricitinib) is indicated for the following conditions:
|
Moderate to Severe Rheumatoid Arthritis For adult patients with moderate to severe active rheumatoid arthritis who have responded inadequately to or are intolerant to one or more disease-modifying anti-rheumatic drugs (DMARDs). Baricinix may be used as monotherapy or in combination with Methotrexate. |
Atopic Dermatitis For adult patients with moderate to severe atopic dermatitis whose disease is not adequately controlled with other systemic therapies. Baricitinib has received USFDA and EMA approval for this indication, demonstrating significant reductions in skin inflammation and itch severity. |
|
Alopecia Areata USFDA-approved for severe alopecia areata in adults. Baricitinib has shown significant hair regrowth in clinical trials for patients suffering from this autoimmune condition that causes patchy or complete hair loss. |
Severe COVID-19 (Emergency Use) Baricitinib received FDA Emergency Use Authorization (EUA) for the treatment of hospitalised adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO) due to severe COVID-19. |
Benefits of Baricinix (Baricitinib) 2mg and 4mg
|
First Once-Daily Oral JAK Inhibitor Baricinix is the first once-daily oral selective JAK1 and JAK2 inhibitor for RA, offering patients a convenient tablet-based alternative to injectable biologics without compromising therapeutic efficacy. |
Multi-Indication Versatility Approved for rheumatoid arthritis, atopic dermatitis, and alopecia areata, with EUA for severe COVID-19. This broad range of approved uses makes Baricinix a highly versatile treatment option for multiple autoimmune conditions. |
Effective Symptom Control Significantly reduces joint pain, tenderness, swelling, and stiffness in RA patients. In clinical trials, Baricitinib demonstrated rapid and sustained improvements in disease activity scores compared to placebo and standard DMARDs. |
|
Affordable Alternative to Olumiant Baricinix contains the same active ingredient as Olumiant by Eli Lilly, at a significantly lower cost. This makes long-term treatment financially accessible for patients in developing and developed countries alike. |
Combination Therapy Compatible Baricinix can be used as monotherapy or in combination with Methotrexate, providing flexibility in treatment planning for physicians managing patients with varying disease activity and treatment histories. |
WHO-GMP and cGMP Certified Produced by Beacon Pharmaceuticals Ltd. under strict WHO-GMP, cGMP, and ISO-certified manufacturing standards, ensuring every batch of Baricinix meets consistent quality, safety, and efficacy requirements. |
How to Take Baricinix (Baricitinib)
Route: Oral, taken by mouth
Standard dose for Rheumatoid Arthritis: 4mg once daily. A dose of 2mg once daily is appropriate for elderly patients aged 75 years and above, patients with a history of chronic or recurrent infections, or patients who have achieved sustained disease control on 4mg and are eligible for dose tapering.
Standard dose for Atopic Dermatitis: 2mg once daily for patients aged 65 years and above. 4mg once daily for other adult patients. A dose reduction to 2mg once daily may be considered for patients who achieve sustained control.
Standard dose for Alopecia Areata: 2mg once daily for patients aged 65 years and above. 4mg once daily for other adult patients.
With food: Can be taken with or without food, at any time of the day
Renal impairment: The recommended dose is 2mg once daily in patients with creatinine clearance between 30 and 60 mL per minute. Baricinix is not recommended for patients with creatinine clearance below 30 mL per minute.
Hepatic impairment: No dose adjustment is required in patients with mild or moderate hepatic impairment. Baricinix is not recommended for patients with severe hepatic impairment.
OAT3 inhibitor co-administration: The recommended dose is 2mg once daily in patients taking strong Organic Anion Transporter 3 (OAT3) inhibitors such as probenecid.
Paediatric use: The safety and efficacy of Baricinix in children and adolescents aged 0 to 18 years have not yet been established. No data are currently available.
Monitoring and Dosage Adjustments
Regular monitoring is essential during Baricinix treatment. Your healthcare provider will monitor for signs of serious infection, as Baricitinib affects the immune system and increases the risk of bacterial, viral, fungal, and opportunistic infections. Monitoring also includes blood counts for lymphopenia, neutropenia, and anaemia, liver function tests, lipid levels including LDL and HDL cholesterol, renal function, and signs of malignancy or thrombosis. Report any fever, unusual fatigue, or signs of infection to your doctor immediately.
Drug Interactions and Important Information
Avoid concomitant use of Baricinix with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants such as azathioprine and cyclosporine, as these combinations may increase the risk of serious infections and immunosuppression.
Reduce the Baricinix dose to 2mg once daily when co-administering with strong OAT3 inhibitors such as probenecid, as these drugs increase Baricitinib plasma exposure. Avoid the use of live vaccines during treatment. Always inform your physician of all medications, supplements, and herbal products you are currently taking before starting Baricinix.
Side Effects and Precautions
|
Common Side Effects Upper respiratory tract infections Nausea Headache Elevated blood cholesterol (LDL and HDL) Acne and folliculitis Thrombocytosis (elevated platelet count) Urinary tract infections Weight gain |
Serious Warnings and Precautions Serious infections including tuberculosis, bacterial, viral and fungal infections. Report any fever, chills, or signs of infection immediately. Venous thromboembolism (VTE) including deep vein thrombosis (DVT) and pulmonary embolism. Use with caution in patients at high risk. Risk of major adverse cardiovascular events (MACE). Use with caution in patients with existing cardiovascular risk factors. Malignancy risk including lymphoma. Avoid in patients with known active malignancy. Not recommended during pregnancy or breastfeeding. Avoid live vaccinations during treatment. Not recommended in patients with severe renal or hepatic impairment. |
Who Should Use Baricinix (Baricitinib)?
Baricinix is suitable for adult patients diagnosed with moderate to severe active rheumatoid arthritis who have had an inadequate response to or intolerance of one or more DMARDs, adult patients with moderate to severe atopic dermatitis not controlled by conventional systemic therapies, and adult patients with severe alopecia areata. It is prescribed by rheumatologists, dermatologists, and specialist physicians experienced in managing autoimmune and inflammatory conditions. A thorough medical assessment including blood counts, renal function, and screening for tuberculosis and hepatitis is required before initiating treatment.
Manufacturer: Beacon Pharmaceuticals Ltd.
Beacon Pharmaceuticals Ltd. is a leading pharmaceutical manufacturer based in Mymensingh, Bangladesh, and the number one oncology and specialty medicine company in the country. Beacon is the first company in Bangladesh to export cancer drugs and currently exports to Asia, Africa, Europe, and Latin America. With more than 200 generic drugs and 65 oncology products in its portfolio, Beacon operates under strict WHO-GMP, cGMP, and ISO-certified standards. Baricinix is one of Beacon’s globally recognised specialty products, offering an affordable and bioequivalent alternative to Olumiant by Eli Lilly at a fraction of the cost.
Global Supplier: Mediaid Pharmacy with Worldwide Shipping
Mediaid Pharmacy is a trusted global supplier of specialty and autoimmune medications. We ensure Baricinix (Baricitinib) is accessible to patients and healthcare providers worldwide through reliable worldwide shipping. Whether you are located in South Asia, the Middle East, Africa, Europe, or beyond, Mediaid Pharmacy provides fast and reliable delivery with full order support. Contact us directly via WhatsApp, phone, or WeChat for pricing, availability, and delivery enquiries.
Why Choose Baricinix (Baricitinib) from Mediaid Pharmacy?
Baricinix represents a major advancement in the treatment of autoimmune and inflammatory conditions. As the generic equivalent of Olumiant by Eli Lilly, it delivers the same active ingredient, Baricitinib, with the same proven JAK1 and JAK2 inhibition mechanism at a dramatically more affordable price. Manufactured by the internationally trusted Beacon Pharmaceuticals Ltd. under WHO-GMP and cGMP standards, and distributed globally by Mediaid Pharmacy, Baricinix gives patients worldwide access to high-quality autoimmune therapy without the financial burden of brand-name alternatives. For patients and physicians seeking a proven, affordable, and accessible Baricitinib option with worldwide delivery, Baricinix from Mediaid Pharmacy is the trusted choice.
Frequently Asked Questions About Baricinix (Baricitinib)
What is Baricinix (Baricitinib) used for?
Baricinix (Baricitinib) is a selective JAK1 and JAK2 inhibitor used to treat moderate to severe rheumatoid arthritis, moderate to severe atopic dermatitis, and severe alopecia areata in adults. It also received FDA Emergency Use Authorization for the treatment of hospitalised adults with severe COVID-19. It works by reducing the abnormal immune signals that cause inflammation and tissue damage in these conditions.
How should I take Baricinix (Baricitinib)?
Baricinix is taken orally once daily, with or without food, at any time of the day. The standard dose for rheumatoid arthritis is 4mg once daily. A 2mg dose is used for elderly patients, those with renal impairment, patients taking strong OAT3 inhibitors, or those who have achieved sustained disease control and are eligible for tapering. Always follow your prescribing physician’s exact instructions.
What strengths is Baricinix (Baricitinib) available in?
Baricinix is available in 2mg and 4mg film-coated tablets, each supplied in a pot of 30 tablets. The 4mg strength is the standard recommended dose for most adult patients with rheumatoid arthritis. The 2mg strength is used when dose reduction is clinically appropriate based on patient age, renal function, or treatment response.
Is Baricinix the same as Olumiant (Baricitinib by Eli Lilly)?
Yes. Baricinix is the generic equivalent of Olumiant. Both contain the same active ingredient, Baricitinib, in the same dosage form and strength. Baricinix is manufactured by Beacon Pharmaceuticals Ltd. in Bangladesh and delivers the same clinical benefits as Olumiant at a significantly lower cost, making it a more accessible option for patients worldwide.
What are the side effects of Baricinix (Baricitinib)?
Common side effects include upper respiratory tract infections, nausea, headache, elevated cholesterol, acne, and urinary tract infections. Serious but less common risks include serious infections, venous thromboembolism, major cardiovascular events, and malignancy. Always consult your physician for a complete assessment of your individual risks and benefits before starting treatment.
Can Baricinix be used with Methotrexate or other medications?
Yes. Baricinix can be used as monotherapy or in combination with Methotrexate for rheumatoid arthritis. However, it should not be combined with other JAK inhibitors, biologic DMARDs, or potent immunosuppressants such as azathioprine or cyclosporine, as these combinations increase the risk of serious infections. Reduce the dose to 2mg when co-administering with strong OAT3 inhibitors such as probenecid.
Is Baricinix (Baricitinib) safe during pregnancy or breastfeeding?
No. Baricinix is not recommended during pregnancy or breastfeeding. Women of childbearing potential must use effective contraception during treatment and for at least one week after the final dose. Please consult your physician before starting treatment if you are pregnant, planning to become pregnant, or breastfeeding.
Can I order Baricinix (Baricitinib) online with worldwide shipping?
Yes. Mediaid Pharmacy supplies Baricinix (Baricitinib) 2mg and 4mg globally with worldwide shipping. Contact us via WhatsApp, phone, or WeChat at +8801773428128 or email us at info@mediaidpharmacy.com to enquire about pricing, availability, and delivery to your country.
Order Baricinix (Baricitinib) 2mg and 4mg with Worldwide Shipping
Phone / WhatsApp / WeChat: +8801773428128 | Email: info@mediaidpharmacy.com
